Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity (scientific article published on 18 November 2009)

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes

Q31157334

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

Q34184221

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress

Q34752002

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Q35134071

Drug changes at the interface between primary and secondary care.

Q35793543

The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials

Q35827865

Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients

Q35846658

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Q36068699

CYP induction-mediated drug interactions: in vitro assessment and clinical implications

Q36485692

The recovery time-course of CYP3A after induction by St John's wort administration

Q36729151

Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans

Q42288254

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping

Q44259193

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects

Q44289523

Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors

Q44431076

Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme

Q44586531

Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.

Q45095090

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

Q45137041

A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry.

Q45146193

Differential impairment of triazolam and zolpidem clearance by ritonavir

Q45285930

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

Q46589222

Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir

Q46972814

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

Q50145200

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

Q51521480

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

Q56829869

What happens to long-term medication when general practice patients are referred to hospital?

Q71523100

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

Q71650801

Acute heart transplant rejection due to Saint John's wort

Q73465831

Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole

Q74204380

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

Q77542483

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

ritonavir

Q422618

P304

page(s)

191-196

P577

publication date

2009-11-18

P1433

published in

Clinical Pharmacology & Therapeutics

Q1101529

P1476

title

Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity

P478

volume

Reverse relations

cites work (P2860)

Q38513275	A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products
Q35919968	An overview of the evidence and mechanisms of herb-drug interactions.
Q56832257	Arzneimittelinteraktionen
Q28468436	Chronic Pain: How Challenging Are DDIs in the Analgesic Treatment of Inpatients with Multiple Chronic Conditions?
Q45995116	Concentration effect relationship of CYP3A inhibition by ritonavir in humans.
Q35725540	Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)
Q48306027	Daily honey consumption does not change CYP3A activity in humans
Q48228997	Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy
Q38974893	Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products.
Q83274402	Drug interactions with herbal medicines
Q48131744	Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity
Q37325581	Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions
Q39497283	Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro
Q34124444	Interactions between herbs and conventional drugs: overview of the clinical data.
Q35023726	Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans
Q37818148	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs
Q37179352	Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1
Q42948755	Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam
Q26784261	Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments
Q50894716	Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz.
Q45841254	Should Midazolam Drug-Drug Interactions be of Concern to Palliative Care Physicians?
Q34359510	The Chinese Herbal Medicine Sophora flavescens Activates Pregnane X Receptor
Q47803945	The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype
Q33604138	Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.
Q39798811	Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.

P356	DOI	10.1038/CLPT.2009.206
P698	PubMed publication ID	19924124